3 New Summary Links to HCV Articles at HIVandHepatitis.com

[Guest guest]

e-Newsletter for Tuesday, April 26, 2011

Hepatitis B and C - Top New Articles

Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

SUMMARY

Addition of the experimental HCV protease inhibitor ABT-450, boosted with

ritonavir, to standard therapy increased the likelihood of complete early

virological response at 12 weeks in previously untreated genotype 1 chronic

hepatitis C patients.

Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C

SUMMARY

Idera Pharmaceuticals has decided to hold off on a planned clinical trial of its

experimental hepatitis C drug IMO-2125, pending further toxicity data from

ongoing animal studies.

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

SUMMARY

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV

coinfected people, an effect that was not fully attributable to increased HIV

viral load or reduced CD4 cell count.

[Guest guest]

e-Newsletter for Tuesday, April 26, 2011

Hepatitis B and C - Top New Articles

Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

SUMMARY

Addition of the experimental HCV protease inhibitor ABT-450, boosted with

ritonavir, to standard therapy increased the likelihood of complete early

virological response at 12 weeks in previously untreated genotype 1 chronic

hepatitis C patients.

Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C

SUMMARY

Idera Pharmaceuticals has decided to hold off on a planned clinical trial of its

experimental hepatitis C drug IMO-2125, pending further toxicity data from

ongoing animal studies.

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

SUMMARY

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV

coinfected people, an effect that was not fully attributable to increased HIV

viral load or reduced CD4 cell count.

[Guest guest]

e-Newsletter for Tuesday, April 26, 2011

Hepatitis B and C - Top New Articles

Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

SUMMARY

Addition of the experimental HCV protease inhibitor ABT-450, boosted with

ritonavir, to standard therapy increased the likelihood of complete early

virological response at 12 weeks in previously untreated genotype 1 chronic

hepatitis C patients.

Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C

SUMMARY

Idera Pharmaceuticals has decided to hold off on a planned clinical trial of its

experimental hepatitis C drug IMO-2125, pending further toxicity data from

ongoing animal studies.

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

SUMMARY

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV

coinfected people, an effect that was not fully attributable to increased HIV

viral load or reduced CD4 cell count.

[Guest guest]

e-Newsletter for Tuesday, April 26, 2011

Hepatitis B and C - Top New Articles

Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

SUMMARY

Addition of the experimental HCV protease inhibitor ABT-450, boosted with

ritonavir, to standard therapy increased the likelihood of complete early

virological response at 12 weeks in previously untreated genotype 1 chronic

hepatitis C patients.

Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C

SUMMARY

Idera Pharmaceuticals has decided to hold off on a planned clinical trial of its

experimental hepatitis C drug IMO-2125, pending further toxicity data from

ongoing animal studies.

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

SUMMARY

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV

coinfected people, an effect that was not fully attributable to increased HIV

viral load or reduced CD4 cell count.